Alnylam Pharmaceuticals delivered a mixed but ultimately bullish Q2 report: AMVUTTRA smashed records with over $1 billion in revenue in just 15 months on the market, fueled by strong global demand and a new China partnership. While they’ve lowered annual revenue guidance due to normalization in early demand, leadership remains confident, citing AMVUTTRA’s clinical strength and expanding patient access. The company is doubling down on innovation—leveraging AI to accelerate drug discovery and delivery—and advancing key pipeline candidates for Huntington’s and Alzheimer’s. With a clear focus on building long-term value through targeted disease leadership and responsible growth, Alnylam is positioning itself as the RNAi powerhouse of the next decade.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
